Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 5/20 | 0.47 |
| ▸ | KLK1 | P06870 | 4/20 | 0.47 |
| ▸ | KLK6 | Q92876 | 4/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 4/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL904391 | 1.00 | PLG (0.47) | PLGKLK1KLK6LOXL2CA12 | |
| SCHEMBL4275810 | 0.84 | ADAMTS4 (0.43) | CA12CA1CA2CA9CA14 | |
| SCHEMBL4275813 | 0.84 | ADAMTS4 (0.43) | CA12CA1CA2CA9CA14 | |
| SCHEMBL27999415 | 0.83 | CFD (0.51) | LOXL2 | |
| SCHEMBL4441635 | 0.83 | CFD (0.50) | PLGKLK1KLK6LOXL2BACE1 | |
| SCHEMBL28377241 | 0.83 | SLC7A5 (0.59) | KDM4ESMN1; SMN2 | |
| SCHEMBL29091831 | 0.82 | POLB (0.47) | CA2KDM4ESMN1; SMN2PLAU | |
| Hydrochloric Acid SCHEMBL3619634 | 0.81 | CFD (0.49) | PLGKLK1KLK6LOXL2BACE1 | |
| SCHEMBL5955038 | 0.81 | SLC1A3 (0.55) | — | |
| SCHEMBL5955043 | 0.81 | SLC1A3 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102725639-A | Positively charged species as binding reagents in the separation of protein aggregates from monomers | NOVARTIS AG | 2012-10-10 | — | — | CN | claimed |
| US-10940159-B2 | Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin | ISLET SCIENCES | 2021-03-09 | — | — | US | disclosed |
| EP-3515926-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | Codexis, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-3471744-A1 | ENGINEERED BETA-GLUCOSIDASES AND GLUCOSYLATION METHODS | Codexis, Inc. (US) | 2019-04-24 | — | — | EP | disclosed |
| CN-104379146-B | Inhibit the composition and method of varial polymerases | 拜奥克里斯特制药公司 | 2018-07-10 | — | — | CN | disclosed |
| WO-2018038906-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | CODEXIS, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| WO-2017218325-A1 | ENGINEERED BETA-GLUCOSIDASES AND GLUCOSYLATION METHODS | CODEXIS, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| CN-107080846-A | Combined immediate/delayed release delivery system for short half-life drugs including remogliflozin | 詹姆斯.特林卡.格林 | 2017-08-22 | — | — | CN | disclosed |
| CN-106573073-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2017-04-19 | — | — | CN | disclosed |
| CN-106456701-A | Modulation of complement activity | RA制药公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-102725639-A | Positively charged species as binding reagents in the separation of protein aggregates from monomers | NOVARTIS AG | 2012-10-10 | — | — | CN | disclosed |
| WO-2012006398-A2 | COMBINATION IMMEDIATE/DELAYED RELEASE DELIVERY SYSTEM FOR SHORT HALF-LIFE PHARMACEUTICALS INCLUDING REMOGLIFLOZIN | BHV PHARMA, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| CN-101072561-B | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS INC | 2011-05-11 | — | — | CN | disclosed |
| EP-1063973-A4 | BIPHASIC CONTROLLED RELEASE DELIVERY SYSTEM FOR HIGH SOLUBILITY PHARMACEUTICALS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2008-11-19 | — | — | EP | disclosed |
| CN-101072561-A | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS INC (US) | 2007-11-14 | — | — | CN | disclosed |
| US-6660300-B1 | Antidiabetic metformin HCl salt; high water solubility and a limited window of absorption; hydrophilic and hydrophobic polymers | BRISTOL-MYERS SQUIBB CO. | 2003-12-09 | — | — | US | disclosed |
| US-6475521-B1 | Biphasic controlled release delivery system for high solubility pharmaceuticals and method | BRISTOL-MYERS SQUIBB CO. | 2002-11-05 | — | — | US | disclosed |
| EP-1063973-A1 | BIPHASIC CONTROLLED RELEASE DELIVERY SYSTEM FOR HIGH SOLUBILITY PHARMACEUTICALS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999047128-A1 | BIPHASIC CONTROLLED RELEASE DELIVERY SYSTEM FOR HIGH SOLUBILITY PHARMACEUTICALS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1993000108-A1 | NOVEL INHIBITORS OF PLATELET AGGREGATION | CORVAS INTERNATIONAL, INC. (US) | 1993-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10940159-B2 | Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin | GLP1R, SLC5A2, SI | PLG 1927/4885KLK1 1968/4885KLK6 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.